+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies

  • ID: 5205788
  • Report
  • November 2020
  • Region: United States
  • 241 Pages
  • Renub Research
The United States Vaccine Market is Poised to Reach US$ 11.4 Billion by 2026

FEATURED COMPANIES

  • GlaxoSmithKline, plc
  • Merck & Co
  • Pfizer, Inc.
  • Sanofi Pasteur

The average human life span has grown significantly primarily due to vaccination. Vaccines have transformed public health throughout the world, especially for children. In the United States, among the various diseases like Influenza, Rotavirus, Hepatitis (Hepatitis A and Hepatitis B), Polio, DTap, HIB, Pneumococcal conjugate, Varicella, MMR, and HPV, influenza is the most common viral infection. Quadrivalent is the most common flu vaccine in the United States, which was licensed in the year 2012.

According to the publisher, the United States Vaccine Market is poised to reach US$ 11.4 Billion by 2026.

Although influenza can catch anyone anytime in the year, usually it spreads between May to October. So in August National Immunization Awareness day is being celebrated to increase the awareness and the importance of vaccination in the nation. These immunization awareness and government initiatives have helped to prevent 2-3 million deaths annually according to the World Health Organisation. There is no other health intervention as simple, powerful, and cost-effective as a ‘vaccine’.

In this report, we have studied key players like GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur, and Pfizer, Inc their trends and implication which has given these companies to view in a strategic way.

Apart from that, companies are evaluated on parameters such as:

  • Overviews
  • Recent Developments
  • Revenues
  • Vaccinations Pipeline & Clinical Trials

The report “United States Vaccine Market By Vaccine Type (Vaccines Market, Immunized Population and Administered Doses), Influenza (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine), Retrovirus, Hepatitis (Hepatitis A and B), Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV) Vaccines Products and Pipeline, Company Analysis (GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur, and Pfizer, Inc.)” provides an all-encompassing analysis of the United States Vaccine Industry.

All the 10 Vaccines have been studied from 3 points:

  • Vaccines Market
  • Immunized Population (Infants)
  • Doses of Vaccines Administered

Vaccine Type - The Report Covers the Market, Immunized Population, and Administered Doses of all the 10 diseases

1. Influenza Vaccines
2. Retrovirus
3. Hepatitis A & B
4. Polio
5. DTaP
6. HIB
7. Pneumococcal conjugate
8. Varicella
9. MMR
10. HPV

All the company analysis has been covered from 4 Viewpoints:

  • Overview
  • Recent Developments
  • Revenue Analysis
  • Vaccinations Pipeline & Clinical Trials

Company Analysis:

  • GlaxoSmithKline, plc
  • Merck & Co
  • Sanofi Pasteur
  • Pfizer, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • GlaxoSmithKline, plc
  • Merck & Co
  • Pfizer, Inc.
  • Sanofi Pasteur

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. United States Vaccine Analysis
5.1 Vaccine Market
5.2 Immunized Population
5.3 Doses of Vaccines Administered

6. Share Analysis
6.1 Market Share by Vaccine Type
6.2 Volume Share by Vaccine Type

7. Disease wise - Vaccines Market& Volume and Forecast
7.1 Influenza Vaccines Market & Types
7.1.1 Trivalent Flu Vaccine
7.1.2 Quadrivalent Flu Vaccine
7.1.3 Administered Doses
7.2 Rotavirus
7.2.1 Vaccines Market
7.2.2 Immunized Population (Infants)
7.2.3 Administered Doses
7.3 Hepatitis B
7.3.1 Vaccines Market
7.3.2 Immunized Population (Infants)
7.3.3 Administered Doses
7.3.4 Hepatitis A
7.4 Polio
7.4.1 Vaccines Market
7.4.2 Immunized Population (Infants + Children)
7.4.3 Administered Doses
7.5 DTaP
7.5.1 Vaccines Market
7.5.2 Immunized Population
7.5.3 Administered Doses
7.6 HIB
7.6.1 Vaccines Market
7.6.2 Immunized Population (Infants)
7.6.3 Administered Doses
7.7 Pneumococcal conjugate
7.7.1 Vaccines Market
7.7.2 Immunized Population (Infants)
7.7.3 Administered Doses
7.8 Varicella
7.8.1 Vaccines Market
7.8.2 Immunized Population (Infants + 4-6 years old)
7.8.3 Administered Doses
7.9 MMR
7.9.1 Vaccines Market
7.9.2 Immunized Population (Infants + 4-6 years old)
7.9.3 Administered Doses
7.10 HPV
7.10.1 Vaccines Market
7.10.2 Immunized Population (Immunized Girl)
7.10.3 Administered Doses

8. Vaccines - Products and Pipeline
8.1 GlaxoSmithKline, plc
8.2 Merck & Co
8.3 Sanofi Pasteur
8.4 Pfizer, Inc.

9. Top Mergers and Acquisitions in the Vaccine Industry

10. Key Players
10.1 GlaxoSmithKline, plc.’s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur’s Vaccines Sales
10.4 Pfizer, Inc.’s Vaccines Sales

List of Tables:
Table-01: United States - Market Share by Vaccine Type (Percentage), 2017 - 2020
Table-02: United States - Forecast For Market Share by Vaccine Type (Percentage), 2020 - 2026
Table-03: United States - Volume Share by Vaccine Type (Percentage), 2017 - 2020
Table-04: United States - Forecast For Volume Share by Vaccine Type (Percentage), 2020 - 2026
Table-05: GlaxoSmithKline, plc. Products & Pipelines
Table-06: Sanofi Pasteur Products & Pipelines
Table-07: Pfizer Products & Pipelines

List of Figures:
Figure-01: United States - Vaccine Market (Million US$), 2016 - 2019
Figure-02: United States - Forecast For Vaccine Market (Million US$), 2020 - 2026
Figure-03: United States - Immunized Population (Million), 2016 - 2019
Figure-04: United States - Vaccine Market (Million US$), 2016 - 2019
Figure-05: United States - Forecast For Vaccine Market (Million US$), 2020 - 2026
Figure-06: United States - Immunized Population (Million), 2016 - 2019
Figure-07: United States - Forecast for Immunized Population (Million) - 2020-2026
Figure-08: United States - Doses of Vaccines Administered (Million), 2016 - 2019
Figure-09: United States - Forecast For Doses of Vaccines Administered (Million), 2020 - 2026
Figure-10: United States - Influenza Vaccines Market (Million US$), 2015 - 2019
Figure-11: United States - Forecast For Influenza Vaccines Market (Million US$), 2020 - 2026
Figure-12: United States - Trivalent flu Vaccines (Million US$), 2014 - 2019
Figure-13: United States - Forecast For Trivalent flu Vaccine (Million US$), 2020 - 2026
Figure-14: United States - Quadrivalent flu Vaccine (Million US$), 2017- 2019
Figure-15: United States - Forecast For Quadrivalent flu Vaccine (Million US$), 2020 - 2026
Figure-16: United States - Administered Doses (Million), 2017 - 2019
Figure-17: United States - Forecast For Administered Doses (Million), 2020 - 2026
Figure-18: United States - Rotavirus Vaccines Market (Million US$), 2015 - 2019
Figure-19: United States - Forecast For Rotavirus Vaccines Market (Million Pound), 2020 - 2026
Figure-20: United States - Rotavirus Immunized Infants (Million), 2015 - 2019
Figure-21: United States - Forecast For Rotavirus Immunized Infants (Million), 2020 - 2026
Figure-22: United States - Rotavirus Administered Doses (Million), 2015 - 2019
Figure-23: United States - Forecast For Rotavirus Administered Doses (Million), 2020 - 2026
Figure-24: United States - Hepatitis B Vaccines Market (Million US$), 2015 - 2019
Figure-25: United States - Forecast For Hepatitis B Vaccines Market (Million US$), 2020 - 2026
Figure-26: United States - Hepatitis B Immunized Population (Million), 2015 - 2019
Figure-27: United States - Forecast For Hepatitis B Immunized Population (Million), 2020 - 2026
Figure-28: United States - Hepatitis B Administered Doses (Million), 2015 - 2019
Figure-29: United States - Forecast For Hepatitis B Administered Doses (Million), 2020 - 2026
Figure-30: United States - Hepatitis A Vaccines Market (Million US$), 2015 - 2019
Figure-31: United States - Forecast For Hepatitis A Vaccines Market (Million US$), 2020 - 2026
Figure-32: United States - Hepatitis A Immunized Infants (Million), 2015 - 2019
Figure-33: United States - Forecast For Hepatitis A Immunized Infants (Million), 2020 - 2026
Figure-34: United States - Hepatitis B Administered Doses (Million), 2015 - 2019
Figure-35: United States - Forecast For Hepatitis B Administered Doses (Million), 2020 - 2026
Figure-36: United States - Polio Vaccine Market (Million US$), 2015 - 2019
Figure-37: United States - Forecast For Polio Vaccine Market (Million US$), 2020 - 2026
Figure-38: United States - Polio Immunized Infants (Million), 2015 - 2019
Figure-39: United States - Forecast For Polio Immunized Infants (Million), 2020 - 2026
Figure-40: United States - Polio Administered Doses (Million), 2015 - 2019
Figure-41: United States - Forecast for Polio Administered Doses (Million), 2020 - 2026
Figure-42: United States - DTaP Vaccines Market (Million US$), 2015 - 2019
Figure-43: United States - Forecast For DTaP Vaccines Market (Million US$), 2020 - 2026
Figure-44: United States - DTaP Immunized Population (Million), 2015 - 2019
Figure-45: United States - Forecast For DTaP Immunized Population (Million), 2020 - 2026
Figure-46: United States - DTaP Administered Doses (Million), 2015 - 2019
Figure-47: United States - Forecast For DTaP Administered Doses (Million), 2020 - 2026
Figure-48: United States - HIB Vaccine Market (Million US$), 2015 - 2019
Figure-49: United States - Forecast For - HIB Vaccine Market (Million US$), 2020 - 2026
Figure-50: United States - HIB Immunized Infants (Million), 2015 - 2019
Figure-51: United States - Forecast For HIB Immunized Infants (Million ), 2020 - 2026
Figure-52: United States - HIB Administered Doses (Million), 2015 - 2019
Figure-53: United States - Forecast For HIB Administered Doses (Million), , 2020 - 2026
Figure-54: United States - Pneumococcal conjugate Vaccines Market (Million US$), 2015 - 2019
Figure-55: United States - Pneumococcal conjugate Vaccines Market (Million US$), 2020 - 2026
Figure-56: United States - Pneumococcal conjugate Immunized Population (Million), 2015 - 2019
Figure-57: United States - Forecast For Pneumococcal conjugate Immunized Population (Million), 2020 - 2026
Figure-58: United States - Pneumococcal conjugate Administered Doses (Million), 2015 - 2019
Figure-59: United States - Forecast For Pneumococcal conjugate Administered Doses (Million), 2020 - 2026
Figure-60: United States - Varicella Vaccines Market (Million US$), 2015 - 2019
Figure-61: United States - Forecast For Varicella Vaccines Market (Million US$), 2020 - 2026
Figure-62: United States - Varicella Immunized Infants (Million), 2015 - 2019
Figure-63: United States - Forecast For Varicella Immunized Infants (Million), 2020 - 2026
Figure-64: United States - Varicella Administered Doses (Million), 2015 - 2019
Figure-65: United States - Forecast For Varicella Administered Doses (Million), 2020 - 2026
Figure-66: United States - MMR Vaccine Market (Million US$), 2015 - 2019
Figure-67: United States - Forecast For MMR Vaccine Market (Million US$), 2020 - 2026
Figure-68: United States - MMR Immunized Population (Million), 2015 - 2019
Figure-69: United States - Forecast For MMR Immunized Population (Million ), 2020 - 2026
Figure-70: United States - Administered Doses (Million), 2015 - 2019
Figure-71: United States - Forecast For Administered Doses (Million), 2020 - 2026
Figure-72: United States - HPV Vaccine Market (Million US$), 2015 - 2019
Figure-73: United States - Forecast For HPV Vaccine Market (Million), 2020 - 2026
Figure-74: United States - HPV Immunized Girl (Million), 2015 - 2019
Figure-75: United States - Forecast For HPV Immunized Girl (Million), 2020 - 2026
Figure-76: United States - HPV Administered Doses (Million), 2015 - 2019
Figure-77: United States - Forecast For HPV Administered Doses (Million ), 2020 - 2026
Figure-78: Global - GlaxoSmithKline, plc.'s Vaccine Revenue (Million US$), 2015 - 2019
Figure-79: Global - Forecast For GlaxoSmithKline plc.'s Vaccine Revenue (Million US$), 2020 - 2026
Figure-80: Global - Merck & Co. Vaccine Revenue (Million US$), 2015 - 2019
Figure-81: Global - Forecast For Merck & Co. Vaccine Revenue (Million US$), 2020 - 2026
Figure-82: Global - Sanofi Pasteur’s Vaccines Revenue (Million US$), 2015 - 2019
Figure-83: Global - Forecast For Sanofi Pasteur’s Vaccines Revenue ( Million US$) 2020 - 2026
Figure-84: Global - Pfizer, Inc.’s Vaccine Revenue (Million US$), 2015 - 2020
Figure-85: Global - Forecast For Pfizer, Inc.’s Vaccine Revenue (Million US$), 2020 - 2026

Note: Product cover images may vary from those shown
  • GlaxoSmithKline, plc
  • Merck & Co
  • Pfizer, Inc.
  • Sanofi Pasteur
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll